We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of ...

Travere Therapeutics stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug, Filspari.

We recently published 10 Stocks With Easy 20-40% Gains. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the last week’s ...

Travere Therapeutics stock tanked yesterday as the company reported its kidney disease drug FILSPARI had failed to meet its key endpoint in a confirmatory study. TVTX shares fell to ~$8 - down 40% for ...

Travere Therapeutics (TVTX) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to a loss of $0.7 per share a year ago ...

Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Travere Therapeutics’ kidney disease strategy has hit a snag. A pivotal phase 3 trial of sparsentan missed its primary endpoint, but the biotech is undeterred, outlining plans to talk to the FDA about ...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, ...

Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday after the company announced that it was informed by the FDA that an advisory committee is no longer needed following ...

Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its endpoints in a phase 3 trial. Travere recently sold two of its drugs for $445 million.